Mylan recalls 4M bottles of cholesterol pill atorvastatin

Mylan is recalling more than 4 million bottles of its cholesterol-lowering atorvastatin in all dosage forms over the possibility that some pills may be contaminated.

Generic makers earn their livings off of volume, so when manufacturing issues lead to a recall, it can sometimes mean big numbers. That is the case with Mylan, which recently began the recall of more than 4 million bottles of cholesterol fighter atorvastatin because some of the tablets might be contaminated.

On March 20, the company began recalling 90 lots of the drug in dose sizes ranging from 10 mg to 80 mg. The FDA posted the recall as a class II on Tuesday.

Mylan said it was recalling the 4,005,177 bottles and 1,527 cartons because of the “potential of an elevated bioburden with identification of objectionable organisms.” The atorvastatin was manufactured at its plant in Morgantown, West Virginia.


Veeva 2020 Unified Clinical Operations Survey

We believe you have the knowledge and expertise to make this year's Veeva 2020 Clinical Operations Report even more robust and insightful than the last. Please take a moment to share your opinion in this 10-minute survey. All qualified respondents will be entered to win a $500 Amazon gift card.

Last fall, the drugmaker recalled more than 100,000 boxes and blister cards of its generic of seizure drug Klonopin that were manufactured at the Morgantown plant. They had been found to be out of specification for an impurity at the 16-month stability testing period.

Not all of its recalls, however, have involved big numbers. In January, Mylan recalled 4,191 bottles of temozolomide capsules, a generic of Merck & Co.’s chemo drug Temodar. The drug is used to treat newly diagnosed glioblastoma, a form of malignant brain tumor. That recall came after Mylan received customer complaints that some of the bottles contained broken or crushed capsules and loose powder in the bottles. They were also manufactured at the West Virginia plant.

Suggested Articles

Fujifilm says it is prepared to ramp up production of Avigan for any country that wants to try it as a potential treatment for COVID-19.

As flights from China contract and prices double, the logistics of getting products out of China is a major challenge. 

A group of drugmakers and others say some federal policies to fight COVID-19 are it making more expensive and harder to get some drugs.